Study summary · research use only
Delta-sleep-inducing peptide reduces CRF-induced corticosterone release
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this rat study, the authors examined effects of delta-sleep-inducing peptide (DSIP), a nonapeptide, on corticotropin releasing factor (CRF)-stimulated release of corticosterone in rats treated with chlorpromazine-morphine-pentobarbital. Intravenous injection of 5-30 micrograms/kg DSIP was associated with a significant reduction in corticosterone levels, while no effect of DSIP was found on corticosterone release elicited by injection of adrenocorticotropic hormone. The authors state these results suggest DSIP attenuates the effects of CRF at the level of the pituitary.
Abstract
It has been reported that delta-sleep-inducing peptide (DSIP) can affect several activities other than sleep, including reduction of stress. We studied the effects of this nonapeptide on corticotropin releasing factor (CRF)-stimulated release of corticosterone in rats treated with chlorpromazine-morphine-pentobarbital. Significant reduction of corticosterone levels were observed after intravenous injection of 5-30 micrograms/kg DSIP. No effect of DSIP was found on the corticosterone release elicited by injection of adrenocorticotropic hormone. The results suggest that DSIP attenuates the effects of CRF at the level of the pituitary.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.